Targeting synthetic lethal interactions is a promising new therapeutic approach to exploit specific changes that occur within cancer cells. Multiple approaches to investigate these interactions have been developed and successfully implemented, including chemical, siRNA, shRNA, and CRISPR library screens. Genome-wide computational approaches, such as DAISY, also have been successful in predicting synthetic lethal interactions from both cancer cell lines and patient samples. Each approach has its advantages and disadvantages that need to be considered depending on the cancer type and its molecular alterations. This review discusses these approaches and examines case studies that highlight their use.
Keywords: CRISPR library; CRISPR screen; DAISY; antitumor; cancer; computational screen; drug discovery; drug screening assays; library screens; neoplasms; shRNA library; shRNA screen; siRNA library; siRNA screen; synthetic lethal interactions; synthetic lethality.